Plasma granulysin concentrations and preeclampsia risk.

Area of Science:

• Immunology
• Obstetrics
• Cellular Biology

Background:

• Preeclampsia shares similarities with graft-host rejection.
• Granulysin, a biomarker of cellular immunity, is secreted by natural killer cells and cytotoxic T lymphocytes.
• Previous studies indicated elevated plasma granulysin in Japanese preeclamptic women.

Purpose of the Study:

• To investigate the association between plasma granulysin levels and preeclampsia in a US cohort.
• To determine if granulysin can serve as a biomarker for preeclampsia risk.

Main Methods:

• A case-control study involving 50 preeclampsia cases and 50 normotensive controls.
• Plasma granulysin levels were measured at delivery using enzyme immunoassay.
• Logistic regression was employed to calculate odds ratios and confidence intervals.

Main Results:

• Plasma granulysin was significantly elevated in preeclampsia cases compared to controls (3.01 vs. 2.22 ng/mL, p<0.01).
• Women with granulysin levels >= 1.89 ng/mL had a 2.9-fold increased risk of preeclampsia (95% CI 1.1-7.8) after adjusting for covariates.
• These findings suggest a predominant Th1 immune status in preeclampsia.

Conclusions:

• Elevated granulysin levels are associated with an increased risk of preeclampsia.
• Granulysin may be a valuable biomarker for preeclampsia.
• Further prospective research is required to ascertain if granulysin is elevated early in pregnancy.